Case Studies

Yunfeng Zhu, PharmD Candidate, Diana M. Sobieraj, PharmD, and Craig I. Coleman, PharmD
Published Online: Wednesday, June 19, 2013
Follow Pharmacy_Times:
Case 1
CS, a 77-year-old man recently diagnosed with atrial fibrillation, presents to your pharmacy with a new prescription for dabigatran etexilate 150 mg twice daily. His past medical history is significant for hypertension and type 2 diabetes (and therefore has a CHADS2 score of 3). He is currently taking metoprolol, lisinopril, and metformin. Upon talking with CS you find out that he uses a pillbox to manage his medications.
As CS’s pharmacist, what important counseling point regarding his dabigatran should you offer?
 
Case 2
PH, a 33-year-old woman, presents to your healthcare clinic with a 10-year history of worsening plaque psoriasis currently affecting 15% of her body. The psoriatic plaques are found on both her trunk and extremities. She has tried a variety of topical steroids and a topical vitamin D analog as well as PUVA and NB-UVB phototherapy treatment in the last 3 years, none of which optimally controlled her psoriasis. She has a history of obesity and was recently diagnosed with hypertension for which olmesartan 20 mg daily was prescribed. Her physician asks for your input on which therapy PH should try next for her psoriasis.
How do you, the pharmacist, respond to PH’s physician?


Related Articles
Not every patient requires an aspirin a day.
The FDA announced today that it will permit the marketing of a mobile medical app that will help patients with diabetes share data from a continuous glucose monitor with other individuals.
The FDA today approved Novartis’ secukinumab (Cosentyx), an interleukin-17A antagonist, for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Preliminary results of an ongoing post-marketing study examining Janssen Pharmaceuticals’ rivaroxaban (Xarelto) in patients with non-valvular atrial fibrillation (NVAF) indicate that the anti-clotting drug’s safety in real-world settings is consistent with the findings of previous phase 3 clinical trials.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$